Evaluation of physicochemical properties, skin permeation and accumulation profiles of ketorolac fatty ester prodrugs

Biological and Pharmaceutical Bulletin

Volumn 30, Issue 11, 2007, Pages 2211-2216

  Bhandari, Krishna Hari ^a   Newa, Madhuri ^a   Yoon, Sung Il ^b   Kim, Jung Sun ^b   Jang, Ki Young ^a   Kim, Jung Ae ^a   Yoo, Bong Kyo ^a   Woo, Jong Soo ^a   Lee, Jae Hwi ^d   Kim, Dae Duk ^c   Choi, Hang Gon ^a   Yong, Chul Soon ^a  

^a Yeungnam University   (South Korea)

^b Dongseo University   (South Korea)

^c Seoul National University   (South Korea)

^d Chung Ang University   (South Korea)

Author keywords

Ketorolac fatty ester prodrug; Skin accumulation; Skin permeation

Indexed keywords

KETOROLAC; KETOROLAC LINOLEATE; KETOROLAC OLEATE; KETOROLAC STEARATE; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG SOLUBILITY; DRUG STRUCTURE; ENZYME STABILITY; HYDROLYSIS; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; SKIN PERMEABILITY; STRATUM CORNEUM;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; ESTERS; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; KETOROLAC; MICE; MICE, INBRED HRS; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; PERMEABILITY; PRODRUGS; SKIN ABSORPTION; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TEMPERATURE;

EID: 36048960251     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.30.2211     Document Type: Article

References (38)

1. Trommer H., Neubert R. H. H., Skin Pharmacol. Physiol., 19, 106-121 (2006).
2. Asbill C. S., Michniak B. B., Pharm. Sci. Technol. Today, 3, 36-41 (2000).
3. Hadgraft J., Eur. J. Drug Metab. Pharmacokin., 21, 165-173 (1996).
4. Potts R. O., Francoeur M. L., Proc. Natl. Acad. Sci. U.S.A., 87, 3871-3873 (1990).
5. Grubauer G., Feingold K. R., Elias P. M., J. Lipid Res., 28, 746-752 (1987).
6. Holleran W. M., Feingold K. R., Man M. Q., Gao W. N., Lee J. M., Elias P. M., J. Lipid Res., 32, 1151-1158 (1991).
7. Holleran W. M., Man M. Q., Gao W. N., Menon G. K., Elias P. M., Feingold K. R., J. Clin. Invest., 88, 1338-1345 (1991).
8. Feingold K. R., Adv. Lipid Res., 24, 57-82 (1991).
9. Man M. Q., Elias P. M., Kenneth R., Feingold K. R., J. Clin. Invest., 92, 791-798 (1993).
10. Man M. Q., Feingold K. R., Elias P. M., Arch. Dermatol., 129, 728-738 (1993).
11. Holleran W. M., Takagi Y., Menon G. K., Legler G., Feingold K. R, Elias P. M., J. Clin. Invest., 91, 1656-1664 (1993).
12. Feingold K. R., Man M. Q., Menon G. K., Cho S. S., Brown B. E., Elias P. M., J. Clin. Invest., 86, 1738-1745 (1990).
13. Tsai J. C., Guy R. H., Thornfeldt C. R., Gao W., Feingold K. R., Elias P. M., J. Pharm. Sci., 85, 643-648 (1996).
14. Elias, P. M., Int. J. Dermatol., 20, 1-9 (1981).
15. Grubauer G., Elias P. M., Feingold K. R., J. Lipid Res., 30, 323-333 (1989).
16. Kanikkannan N., Kandimalla K., Lamba S. S., Singh M., Curr. Med. Chem., 7, 593-608 (2000).
17. Aungst B., Rogers N., Shefter E., Int. J. Pharm., 33, 225-234 (1986).
18. Lee C., Uchida T., Noguchi E., Kim N., Goto S., J. Pharm. Sci., 82, 1155-1159 (1993).
19. Sloan K. B., Beall H. D., Taylor H. E., Int. J. Pharm., 171, 185-193 (1998).
20. Andega S., Kanikkannan N., Singh M., J. Controlled Release, 77, 17-25 (2001).
21. Kanikkannan N., Singh M., Int. J. Pharm., 248, 219-228 (2002).
22. Cooper E. R., Merritt E. W., Smith R. L., J. Pharm. Sci., 74, 688-689 (1985).
23. Goodman M., Barry B. W., Int. J. Pharm., 57, 29-40 (1989).
24. Williams A. C., Barry B. W., Crit. Rev. Ther. Drug Carrier Syst., 9, 305-353 (1992).
25. Roy S. D., Manoukian E., J. Pharm. Sci., 83, 1548-1553 (1994).
26. Doh H. J., Cho W. J., Yong C. S., Choi H. G., Kim J. S., Lee C. H., Kim D. D., J. Pharm. Sci., 92, 1008-1017 (2003).
27. Kim B. Y., Doh H. J., Le T. N., Cho W. J., Yong C. S., Choi H. G., Kim J. S., Lee C. H., Kim D. D., Int. J. Pharm., 293, 193-202 (2005).
28. Setoh K., Murakami M., Araki N., Fujita T., Yamamoto A., Muranishi S., J. Pharm. Pharmacol., 47, 808-811 (1995).
29. Ettmayer P., Amidon G. L. B., Clement B., J. Med. Chem., 47, 2393-2404 (2004).
30. Shah H. S., Tojo K., Chien Y. W., Int. J. Pharm., 86, 167-173 (1992).
31. Kuo P. C., Liu J. C., Chang S. F., Chien Y. W., Drug Dev. Ind. Pharm., 15, 1199-1215 (1989).
32. Chris A. J., Charles M. H., Chris M., J. Drug Targeting, 11, 433-441 (2003).
33. Bendas B., Schmalfuss U., Neubert R., Int. J. Pharm., 116, 19-30 (1995).
34. Squillante E., Needham T., Maniar A., Kislalioglu S., Zia H., Eur. J. Pharm. Biopharm., 46, 265-271 (1998).
35. Arellano A., Santoyo S., Martin C., Ygartua P., Eur. J. Pharm. Sci., 7, 129-135 (1999).
36. Gwak H. S., Chun K. I., Int. J. Pharm., 236, 57-64 (2002).
37. Young A. C., Gwak H. S., Drug Dev. Ind. Pharm., 30, 557-564 (2004).
38. Lee A. J., King J. R., Barett D. A., J. Controlled Release, 45, 141-151 (1997).